Catriona Yale Sells 3,871 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 3,871 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $27.56, for a total value of $106,684.76. Following the sale, the insider now directly owns 75,294 shares in the company, valued at $2,075,102.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Trading Up 1.2 %

NASDAQ AKRO traded up $0.32 during trading hours on Wednesday, hitting $26.96. 485,803 shares of the company were exchanged, compared to its average volume of 933,663. Akero Therapeutics, Inc. has a 52 week low of $11.25 and a 52 week high of $53.00. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $26.22 and a 200 day moving average price of $23.95. The stock has a market cap of $1.86 billion, a PE ratio of -8.43 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AKRO has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. Finally, Wolfe Research assumed coverage on Akero Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.13.

Hedge Funds Weigh In On Akero Therapeutics

A number of large investors have recently made changes to their positions in AKRO. Quarry LP raised its position in Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after purchasing an additional 500 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after buying an additional 1,030 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after buying an additional 1,183 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Akero Therapeutics by 15.6% during the 1st quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after acquiring an additional 1,858 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Akero Therapeutics by 24.4% during the 1st quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock valued at $379,000 after acquiring an additional 2,945 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.